EU PRAC Updates Desogestrel Contraceptive Safety July 2026

• PRAC agreed on new safety information for desogestrel- and etonogestrel-containing contraceptives.
• These updates are expected to impact labeling and regulatory requirements for these products.
• Litfulo, a treatment for alopecia areata, was approved by PRAC in the EU.

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) met from July 6-9, 2026.

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) met from July 6-9, 2026. During this meeting, the committee reached an agreement on new safety information for desogestrel- and etonogestrel-containing contraceptives. These updates are expected to impact labeling and regulatory requirements for these products. Additionally, PRAC approved Litfulo, a treatment for alopecia areata, marking a significant development in the EU's pharmaceutical landscape.

The European Medicines Agency (EMA) is responsible for ensuring the safety and efficacy of medicines across the European Union. The Pharmacovigilance Risk Assessment Committee (PRAC) plays a crucial role in this process, reviewing and assessing new data on existing and emerging medicines. PRAC's decisions are guided by EU regulations and guidelines, which aim to protect public health while facilitating innovation in the pharmaceutical sector.

Lawyers and compliance officers should be aware of these developments, as they may require updates to labeling or regulatory requirements for desogestrel- and etonogestrel-containing contraceptives. The EU's approval of Litfulo also has implications for the treatment of alopecia areata in Europe. As the pharmaceutical landscape continues to evolve, it is essential for stakeholders to stay informed about changes in regulations and guidelines that may impact their products or services.

Lawyers and compliance officers should watch for potential changes to labeling or regulatory requirements for desogestrel- and etonogestrel-containing contraceptives, as well as the EU's approval of Litfulo for treating alopecia areata.

Source: Original reporting via EMA